253 related articles for article (PubMed ID: 27187683)
1. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Chugh S; Meza J; Sheinin YM; Ponnusamy MP; Batra SK
Br J Cancer; 2016 Jun; 114(12):1376-86. PubMed ID: 27187683
[TBL] [Abstract][Full Text] [Related]
2. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth.
Taniuchi K; Cerny RL; Tanouchi A; Kohno K; Kotani N; Honke K; Saibara T; Hollingsworth MA
Oncogene; 2011 Dec; 30(49):4843-54. PubMed ID: 21625220
[TBL] [Abstract][Full Text] [Related]
4. Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Barkeer S; Chugh S; Karmakar S; Kaushik G; Rauth S; Rachagani S; Batra SK; Ponnusamy MP
BMC Cancer; 2018 Nov; 18(1):1157. PubMed ID: 30466404
[TBL] [Abstract][Full Text] [Related]
5. Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice.
Chugh S; Barkeer S; Rachagani S; Nimmakayala RK; Perumal N; Pothuraju R; Atri P; Mahapatra S; Thapa I; Talmon GA; Smith LM; Yu X; Neelamegham S; Fu J; Xia L; Ponnusamy MP; Batra SK
Gastroenterology; 2018 Nov; 155(5):1608-1624. PubMed ID: 30086262
[TBL] [Abstract][Full Text] [Related]
6. A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Sheta R; Woo CM; Roux-Dalvai F; Fournier F; Bourassa S; Droit A; Bertozzi CR; Bachvarov D
J Proteomics; 2016 Aug; 145():91-102. PubMed ID: 27095597
[TBL] [Abstract][Full Text] [Related]
7. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Wang ZQ; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Bachvarov D
Oncotarget; 2014 Jan; 5(2):544-60. PubMed ID: 24504219
[TBL] [Abstract][Full Text] [Related]
8. The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
Sheta R; Bachvarova M; Macdonald E; Gobeil S; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071912
[TBL] [Abstract][Full Text] [Related]
9. EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression.
Chen C; Wang X; Fang J; Xue J; Xiong X; Huang Y; Hu J; Ling K
Oncotarget; 2017 Jun; 8(26):42621-42637. PubMed ID: 28388589
[TBL] [Abstract][Full Text] [Related]
10. Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas.
Yamamoto S; Nakamori S; Tsujie M; Takahashi Y; Nagano H; Dono K; Umeshita K; Sakon M; Tomita Y; Hoshida Y; Aozasa K; Kohno K; Monden M
Pathobiology; 2004; 71(1):12-8. PubMed ID: 14555840
[TBL] [Abstract][Full Text] [Related]
11. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
12. SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells.
Li S; Hong H; Lv H; Wu G; Wang Z
Med Sci Monit; 2016 May; 22():1593-600. PubMed ID: 27170223
[TBL] [Abstract][Full Text] [Related]
13. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934
[TBL] [Abstract][Full Text] [Related]
15. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
16. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
Qi T; Han J; Cui Y; Zong M; Liu X; Zhu B
J Clin Pathol; 2008 Jan; 61(1):49-58. PubMed ID: 17412869
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
18. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
19. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer.
Rawnaq T; Dietrich L; Wolters-Eisfeld G; Uzunoglu FG; Vashist YK; Bachmann K; Simon R; Izbicki JR; Bockhorn M; Güngör C
Mol Cancer Res; 2014 May; 12(5):670-80. PubMed ID: 24567526
[TBL] [Abstract][Full Text] [Related]
20. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression.
Khan S; Sikander M; Ebeling MC; Ganju A; Kumari S; Yallapu MM; Hafeez BB; Ise T; Nagata S; Zafar N; Behrman SW; Wan JY; Ghimire HM; Sahay P; Pradhan P; Chauhan SC; Jaggi M
Oncogene; 2017 Jan; 36(4):491-500. PubMed ID: 27321183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
